Aarti Pharmalabs Limited's Credit Rating Upgraded to CRISIL AA-/Stable, Reflecting Strong Financial Health and Business Prospects
Mumbai, Maharashtra, India – July 17, 2025 : Aarti Pharmalabs Limited, a leading manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, xanthine derivatives and CDMO service provider, today announced that CRISIL Ratings, India's foremost credit rating agency, has upgraded the company's long-term credit rating to CRISIL AA-/Stable from the previous A+/Positive.
This significant upgrade underscores Aarti Pharmalabs Limited's robust financial performance, sound management practices, and strengthening business profile. The "CRISIL AA-" rating signifies a high degree of safety regarding the timely servicing of financial obligations and indicates very low credit risk. The "Stable" outlook further reinforces CRISIL's expectation that the company's strong credit profile will be maintained over the medium term.
"We are incredibly pleased with CRISIL's decision to upgrade our credit rating, this upgrade is a testament to our relentless focus on operational excellence, prudent financial management, and strategic investments in expanding our capabilities. It reflects the dedication of our entire team and our commitment to sustainable growth." said Mr. Rashesh Gogri, Chairperson.
The upgrade from an "A+/Positive" outlook to an actual "AA-/Stable" rating indicates that the positive factors identified by CRISIL previously have materialized, leading to a tangible improvement in Aarti Pharmalabs Limited's creditworthiness.
This enhanced credit rating is expected to further strengthen Aarti Pharmalabs Limited's standing with lenders, investors, and other stakeholders, potentially facilitating access to capital on more favourable terms and reinforcing confidence in the company's long-term prospects.
About Aarti Pharmalabs Limited:
Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. Since its demerger in 2022, Aarti Pharmalabs Limited has accelerated its focus on innovation, sustainability, and global leadership in the pharmaceutical and nutraceutical sectors. The company specializes in producing generic APIs, intermediates, and xanthine derivatives (including Synthetic Caffeine). Additionally, Aarti Pharmalabs Limited offers comprehensive CDMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies, with dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products.
About CRISIL Ratings Limited:
Crisil Ratings Limited (A subsidiary of Crisil Limited) provides ratings, research, and risk and policy advisory services. Since its inception in 1987, CRISIL has played a pivotal role in assessing the creditworthiness of companies, financial institutions, and government bodies across India, thereby contributing significantly to the transparency and efficiency of the Indian financial markets. Their independent and rigorous analyses are widely trusted by investors, lenders, and other stakeholders for informed decision-making.
Contact:
Name of Contact: Mr. Anuj Sonpal
Email: aarti@valoremadvisors.com
Contact Number: +91-22-4903 9500
Website: www.aartipharmalabs.com
